

**REMARKS**

Claims 1-43 are pending in the present application and are presented for examination.


***Restriction Requirement:***

Applicants elect Group I drawn to compounds of formula I wherein D and X both are C-R; R is H; R3, R4, and R5 are H; R2 is H or alkyl; and R1 is phenyl(not fused), for proceeding with prosecution on the merits. Claims 1(in part), 3, 5, 8-12, 14-39, 40 (in part), 41 and 42 read on Group I.


***Election Requirement:***

The Office Action has also required an election of species. In response, Applicants elect as a single species the compound of Example 12 found on page 47, lines 23-30 of the specification. The compound of Example 12 is:

(2E)-N-(3-benzoylphenyl)-3-(1H-indazol-3-yl)-2-propenamide.



The elected species is found in the generic formula 1 of claim 1 as follows:



(I)

D is C-R.

X is C-R.

R is H.

R<sup>1</sup> is -(Q)<sub>m</sub>-(Q<sup>1</sup>)<sub>n</sub>-(Q<sup>2</sup>)<sub>p</sub> whereQ is arylene (specifically phenylene) and q is 1; Q<sup>1</sup> is C(O) and n is 1; and Q<sup>2</sup> is aryl (specifically phenyl) and p is 1.R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are H.

Applicants note that upon allowance of a generic claim, Applicant will be entitled to consideration of additional species which depend from or otherwise require all the limitations of the allowable generic claim.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to affect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



John L. Lemanowicz  
Attorney for Applicant  
Registration No. 37,380

Date: 4/29/08

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive

P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-8247 Facsimile: 919-483-7988